Cancer/Tumor Profiling Market Analysis Report 2018-2025 by Application (Diagnostics, Personalized Medicine), & Technique (Proteomics, Metabolomics, Epigenetics) - ResearchAndMarkets.com

The "Cancer/Tumor Profiling Market Analysis Report By Technology, By Application (Diagnostics, Personalized Medicine), By Technique (Proteomics, Metabolomics, Epigenetics), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global cancer/tumor profiling market size is expected to reach USD 21.08 billion by 2025, exhibiting a CAGR of 8.8%

Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Further key findings from the report suggest:

• Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption. The segment is expected to fuel exhibit a CAGR of over 9.0%
• Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
• Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well
• Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Cancer Tumor Profiling Market Variables, Trends & Scope

3.1 Market segmentation & scope

3.1.1 Market Driver Analysis

3.1.1.1 Use of omics sciences in the development of personalized medicine

3.1.1.2 Developing trend of PoC cancer tests

3.1.1.3 Technological advancements

3.1.2 Market Restrain Analysis

3.1.2.1 High capital and low benefit ratio of biomarkers

3.2 Penetration & growth prospect mapping

3.3 Cancer tumor profiling - SWOT Analysis, By Factor (political & legal, economic and technological)

3.4 Industry Analysis - Porter's

Chapter 4 Cancer Tumor Profiling: Technique Type Estimates & Trend Analysis

4.1 Cancer tumor profiling market: Technique Scope movement analysis

4.2 Genomics

4.3 Proteomics

4.4 Metabolomics

4.5 Epigenetics

Chapter 5 Cancer Tumor Profiling: Technology Estimates & Trend Analysis

5.1 Cancer tumor profiling market: Technology movement analysis

5.2 Sequencing Technologies

5.2.1 Sequencing technologies market, 2014 - 2025 (USD Million)

5.2.2 Next Generation Sequencing(NGS)

5.2.3 Sanger Sequencing

5.2.4 Pyro Sequencing

5.3 In Situ Hybridization

5.4 Immunohistochemistry

5.5 Quantitative PCR (qPCR)

5.6 Microarray

Chapter 6 Cancer Tumor Profiling: Application Estimates & Trend Analysis

6.1 Cancer tumor profiling market: application movement analysis

6.2 Personalized Cancer Medicine

6.2.1 Personalized cancer medicine market, 2014 - 2025 (USD Million)

6.3 Oncological Diagnostics

6.3.1 Oncological diagnostics market, 2014 - 2025 (USD Million)

6.4 Research

6.4.1 Research market, 2014 - 2025 (USD Million)

6.4.2 Cancer research

6.4.3 Biomarker discovery

Chapter 7 Cancer Tumor Profiling: Regional Estimates & Trend Analysis, by Application, Technique and Technology scope

7.1 Cancer tumor profiling market share by region, 2016 & 2025

7.2 North America

7.2.1 North America Cancer tumor profiling market, 2014 - 2025 (USD Million)

7.2.2 U.S.

7.2.3 Canada

7.3 Europe

7.3.1 Europe Cancer tumor profiling market, 2014 - 2025 (USD Million)

7.3.2 Germany

7.3.3 U.K.

7.4 Asia Pacific

7.4.2 China

7.4.3 Japan

7.5 Latin America

7.5.2 Brazil

7.5.2.1 Brazil Cancer tumor profiling market, 2014 - 2025 (USD Million)

7.6 Middle East and Africa

7.6.1 Middle East and Africa Cancer tumor profiling market, 2014 - 2025 (USD Million)

7.6.2 South Africa

Chapter 8 Competitive Landscape

8.1 Strategy framework

8.2 Market participation categorization

• Illumina, Inc.
• Qiagen N.V.
• Neogenomics Laboratories Inc.,
• HTG Molecular Diagnostics, Inc.,
• Genomic Health Inc.,
• Caris Life Sciences
• Helomics Corporation
• NanostringTechologies
• Oxford Gene Technology
• Ribomed Biotechnologies, Inc.,
• Personal Genome Diagnostics
• GenomeDX
• Guardant Health
• Foundation Medicine

For more information about this report visit https://www.researchandmarkets.com/r/9553qh

View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005434/en/